Progress in the development of matrix metalloproteinase inhibitors

被引:88
作者
Tu, GuoGang [1 ,2 ]
Xu, WenFang
Huang, HuiMing [2 ]
Li, ShaoHua [2 ]
机构
[1] Shandong Univ, Dept Med Chem, Sch Pharmaceut Sci, Jinan 250012, Peoples R China
[2] NanChang Univ, Coll Med, Dept Pharm, Nanchang 330006, Peoples R China
关键词
matrix metalloproteinases; MMP inhibitors; Zinc-binding groups; cancer; computer-aided drug design; angiogenesis; metastasis; proteases;
D O I
10.2174/092986708784567680
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Matrix metalloproteinases ( MMPs) are a family of zinc-dependent proteinases involved in the degradation and remodeling of extracellular matrix proteins that are associated with the tumorigenic process. MMPs promote tumor invasion and metastasis, regulating host defense mechanisms and normal cell function. Thus, MMP inhibitors (MMPIs) are expected to be useful for the treatment of diseases such as cancer, osteoarthritis, and rheumatoid arthritis. A vast number of MMPIs have been developed in recent years. With the failure of these inhibitors in clinical trials, more efforts have been directed to the design of specific inhibitors with different Zn-binding groups. This review summarizes the current status of MMPIs, the design of small molecular weight MMPIs, a brief description of available three-dimensional MMP structures, a review of the proposed therapeutic utility of MMPIs, and a clinical update of compounds that have entered clinical trials in humans.
引用
收藏
页码:1388 / 1395
页数:8
相关论文
共 40 条
[1]  
ANDREWS RC, 2000, Patent No. 0012082
[2]   Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis [J].
Bergers, G ;
Brekken, R ;
McMahon, G ;
Vu, TH ;
Itoh, T ;
Tamaki, K ;
Tanzawa, K ;
Thorpe, P ;
Itohara, S ;
Werb, Z ;
Hanahan, D .
NATURE CELL BIOLOGY, 2000, 2 (10) :737-744
[3]   Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer [J].
Bissett, D ;
O'Byrne, KJ ;
von Pawel, J ;
Gatzemeier, U ;
Price, A ;
Nicolson, M ;
Mercier, R ;
Mazabel, E ;
Penning, C ;
Zhang, MH ;
Collier, MA ;
Shepherd, FA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :842-849
[4]   Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial [J].
Bramhall, SR ;
Rosemurgy, A ;
Brown, PD ;
Bowry, C ;
Buckels, JAC .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (15) :3447-3455
[5]   Recent non-hydroxamate matrix metalloproteinase inhibitors [J].
Breuer, E ;
Frant, J ;
Reich, R .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2005, 15 (03) :253-269
[6]   The active site of a zinc-dependent metalloproteinase influences the computed pKa of ligands coordinated to the catalytic zinc ion [J].
Cross, JB ;
Duca, JS ;
Kaminski, JJ ;
Madison, VS .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2002, 124 (37) :11004-11007
[7]   New functions for the matrix metalloproteinases in cancer progression [J].
Egeblad, M ;
Werb, Z .
NATURE REVIEWS CANCER, 2002, 2 (03) :161-174
[8]   Anoikis mechanisms [J].
Frisch, SM ;
Screaton, RA .
CURRENT OPINION IN CELL BIOLOGY, 2001, 13 (05) :555-562
[9]   Bioactive marine metabolites, Part 124.: Ageladine A:: An antiangiogenic matrixmetalloproteinase inhibitor from the marine sponge Agelas nakamurai [J].
Fujita, M ;
Nakao, Y ;
Matsunaga, S ;
Seiki, M ;
Itoh, Y ;
Yamashita, J ;
van Soest, RWM ;
Fusetani, N .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2003, 125 (51) :15700-15701
[10]   Isolation and structure elucidation of two phosphorylated sterol sulfates, MT1-MMP inhibitors from a marine sponge Cribrochalina sp.:: revision of the structures of haplosamates A and B [J].
Fujita, M ;
Nakao, Y ;
Matsunaga, S ;
Seiki, M ;
Itoh, Y ;
van Soest, RWM ;
Heubes, M ;
Faulkner, DJ ;
Fusetani, N .
TETRAHEDRON, 2001, 57 (18) :3885-3890